Last Updated on October 9, 2024 by The Health Master
Guidelines
In a significant move to bolster the pharmaceutical industry, the Department of Pharmaceuticals (DoP) has once again revised the guidelines for the Strengthening of Pharmaceutical Industry (SPI) scheme.
This latest update focuses on enhancing the Revamped Pharmaceutical Technology Upgradation Assistance Scheme (RPTUAS) by increasing the maximum incentive and including expenditure on production equipment for subsidy calculations.
The Department notified modifications on September 17, also removing the requirement for a detailed gap analysis for online application for the sub-scheme, replacing it with a normal gap analysis.
Key Revisions to RPTUAS
- Increased Maximum Incentive: The maximum limit of incentive under the scheme has been raised from Rs. 1 crore to Rs. 2 crore, offering greater financial support to pharmaceutical units.
- Inclusion of Production Equipment: Expenditure incurred on production equipment will now be considered for calculating the subsidy amount, expanding the scope of eligible expenses.
- Simplified Application Process: The requirement for a detailed gap analysis for online applications has been removed, streamlining the application process for MSMEs.
Benefits for Pharmaceutical Units
- Enhanced Financial Assistance: The increased maximum incentive provides a more substantial financial boost to pharmaceutical units, enabling them to invest in upgrades and expansions.
- Expanded Eligibility: The inclusion of production equipment in eligible expenses broadens the range of activities that can be supported by the subsidy, making it more accessible to units with diverse needs.
- Simplified Application Process: The removal of the detailed gap analysis requirement reduces the administrative burden on applicants, making it easier for MSMEs to participate in the scheme.
Eligibility Criteria and Support
- Average Turnover: Units with an average turnover from Rs. 1 crore to less than Rs. 50 crore can avail of a 20% incentive, while those with a turnover from Rs. 50 crore to less than Rs. 250 crore can receive a 15% incentive. Units with a turnover from Rs. 250 crore to less than Rs. 500 crore are eligible for a 10% incentive.
- Subsidy Disbursement: The Scheme Steering Committee (SSC) will review applications and recommend subsidy amounts. 50% of the eligible amount (up to Rs. 1 crore) will be released as the first installment, and the remaining 50% (up to Rs. 2 crore) will be released upon completion of requirements.
Government’s Commitment to Pharmaceutical MSMEs
The DoP’s revised guidelines demonstrate the government’s ongoing commitment to supporting pharmaceutical MSMEs and promoting their growth.
By providing enhanced financial assistance and streamlining the application process, the government aims to enable these units to upgrade their facilities, improve their competitiveness, and contribute to the overall development of the pharmaceutical industry.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
Maharashtra FDA cracks down on ayurvedic manufacturer DMROA
CDSCO Updates Guidance for Zonal, Sub-Zonal, and Port Offices
DCC recommends to address drug Brand Name Confusion in India
USFDA Inspection successfully completed at Indian firm Laurus Labs
CDSCO to switch to online submission of Form 44
USFDA inspection finds these lapses at Zydus Lifesciences
Joint raid exposes illegal sale of Tramadol
DCA Telangana seizes huge quantity of Cough Syrup
Key components of Uniform Code for Marketing Practices in Medical Devices (UCMPMD) 2024
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
